시장보고서
상품코드
1166050

펩티드 치료제 시장 : 세계 업계 분석, 규모, 점유율, 성장, 동향, 예측(2022-2031년)

Peptide Therapeutics Market (Application: Cancer, Metabolic, CVD, Respiratory, GIT, Anti-infective, Dermatology, CNS, and Renal) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031

발행일: | 리서치사: Transparency Market Research | 페이지 정보: 영문 211 Pages | 배송안내 : 2-10일 (영업일 기준)

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 펩티드 치료제(Peptide Therapeutics) 시장에 대해 조사했으며, 시장 개요, 2022-2031년 예측, 용도별, 투여 경로별/유형별/기술별/분자 유형별/API 펩티드 유형별/지역별 동향, 시장 진출기업 프로파일 등의 정보를 제공합니다.

목차

제1장 서문

제2장 전제조건과 조사 방법

제3장 주요 요약 : 세계의 펩티드 치료제 시장

제4장 시장 개요

  • 서론
  • 개요
  • 시장 역학
  • 세계의 펩티드 치료제 시장 분석과 예측, 2017-2031년

제5장 주요 인사이트

제6장 세계의 펩티드 치료제 시장 분석과 예측, 용도별

  • 서론과 정의
  • 주요 조사 결과/개발
  • 매출 예측, 용도별, 2017-2031년
    • 대사
    • CVD
    • 호흡기
    • 소화관
    • 항감염증
    • 피부과
    • 중추신경계
    • 신장
  • 용도별 시장 매력 분석

제7장 세계의 펩티드 치료제 시장 분석과 예측, 투여 경로별

  • 서론과 정의
  • 주요 조사 결과/개발
  • 매출 예측, 투여 경로별, 2017-2031년
    • 비경구
    • 경구
  • 투여 경로별 시장 매력 분석

제8장 세계의 펩티드 치료 시장 분석과 예측, 유형별

  • 서론과 정의
  • 주요 조사 결과/개발
  • 매출 예측, 유형별, 2017-2031년
    • 혁신 의약품
    • 제네릭 의약품
  • 유형별 시장 매력 분석

제9장 세계의 펩티드 치료제 시장 분석과 예측, 기술별

  • 서론과 정의
  • 주요 조사 결과/개발
  • 매출 예측, 기술별, 2017-2031년
    • Liquid Phase
    • Solid Phase
    • Hybrid Phase
  • 기술별 시장 매력 분석

제10장 세계의 펩티드 치료제 시장 분석과 예측, 분자 유형별

  • 서론과 정의
  • 주요 조사 결과/개발
  • 매출 예측, 분자 유형별, 2017-2031년
    • Vasopressin
    • Somatostatin
    • Calcitonin
    • Natriuretic
  • 분자 유형별 시장 매력 분석

제11장 세계의 펩티드 치료 시장 분석과 예측, API 펩티드 유형별

  • 서론과 정의
  • 주요 조사 결과/개발
  • 매출 예측, API 펩티드 유형별, 2017-2031년
    • 사내
    • CMO
  • API 펩티드 유형별 시장 매력 분석

제12장 세계의 펩티드 치료제 시장 분석과 예측, 지역별

  • 주요 조사 결과
  • 매출 예측, 지역별
    • 북미
    • 유럽
    • 아시아태평양
    • 라틴아메리카
    • 중동 및 아프리카
  • 지역별 시장 매력 분석

제13장 북미의 펩티드 치료제 시장 분석과 예측

제14장 유럽의 펩티드 치료제 시장 분석과 예측

제15장 아시아태평양 펩티드 치료 시장 분석과 예측

제16장 라틴아메리카의 펩티드 치료제 시장 분석과 예측

제17장 중동 및 아프리카의 펩티드 치료제 시장 분석과 예측

제18장 경쟁 구도

  • 시장 참여 기업 - 경쟁 매트릭스(층 및 기업 규모별)
  • 시장 점유율 분석, 기업별, 2021년
  • 기업 개요
    • Amgen, Inc.
    • Bachem Holding AG
    • Eli Lilly and Company
    • F. Hoffmann-La Roche Ltd.
    • GlaxoSmithKline plc
    • Novartis AG
    • Pfizer, Inc.
    • Sanofi
    • Takeda Pharmaceutical Company Limited
    • Teva Pharmaceutical Industries Ltd.
LSH 22.12.13

TMR's report on the global peptide therapeutics market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2022 to 2031. The report provides revenue of the global peptide therapeutics market for the period 2017-2031, considering 2021 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global peptide therapeutics market from 2022 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the peptide therapeutics market.

The report delves into the competitive landscape of the global peptide therapeutics market. Key players operating in the global peptide therapeutics market have been identified and each one of these has been profiled, in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are attributes of players in the global peptide therapeutics market profiled in this report.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Peptide Therapeutics Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Definition
    • 4.1.2. Industry Evolution / Developments
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global Peptide Therapeutics Market Analysis and Forecast, 2017-2031

5. Key Insights

  • 5.1. White Space Analysis
  • 5.2. Porter's Analysis
  • 5.3. Pipeline Analysis (Phase III)
  • 5.4. Peptide Drug Chemical Structure Trend Analysis
  • 5.5. Separation Media for Peptide Drug Manufacturing
  • 5.6. Covid-19 Impact Analysis

6. Global Peptide Therapeutics Market Analysis and Forecast, by Application

  • 6.1. Introduction & Definition
  • 6.2. Key Findings / Developments
  • 6.3. Market Value Forecast, by Application, 2017-2031
    • 6.3.1. Cancer
    • 6.3.2. Metabolic
    • 6.3.3. CVD
    • 6.3.4. Respiratory
    • 6.3.5. GIT
    • 6.3.6. Anti-infective
    • 6.3.7. Dermatology
    • 6.3.8. CNS
    • 6.3.9. Renal
  • 6.4. Market Attractiveness Analysis, by Application

7. Global Peptide Therapeutics Market Analysis and Forecast, by Route of Administration

  • 7.1. Introduction & Definition
  • 7.2. Key Findings / Developments
  • 7.3. Market Value Forecast, by Route of Administration, 2017-2031
    • 7.3.1. Parenteral
    • 7.3.2. Oral
  • 7.4. Market Attractiveness Analysis, by Route of Administration

8. Global Peptide Therapeutics Market Analysis and Forecast, by Type

  • 8.1. Introduction & Definition
  • 8.2. Key Findings / Developments
  • 8.3. Market Value Forecast, by Type, 2017-2031
    • 8.3.1. Innovative
    • 8.3.2. Generic
  • 8.4. Market Attractiveness Analysis, by Type

9. Global Peptide Therapeutics Market Analysis and Forecast, by Technology

  • 9.1. Introduction & Definition
  • 9.2. Key Findings / Developments
  • 9.3. Market Value Forecast, by Technology, 2017-2031
    • 9.3.1. Liquid Phase
    • 9.3.2. Solid Phase
    • 9.3.3. Hybrid Phase
  • 9.4. Market Attractiveness Analysis, by Technology

10. Global Peptide Therapeutics Market Analysis and Forecast, by Type of Molecule

  • 10.1. Introduction & Definition
  • 10.2. Key Findings / Developments
  • 10.3. Market Value Forecast, by Type of Molecule, 2017-2031
    • 10.3.1. Vasopressin
    • 10.3.2. Somatostatin
    • 10.3.3. Calcitonin
    • 10.3.4. Natriuretic
  • 10.4. Market Attractiveness Analysis, by Type of Molecule

11. Global Peptide Therapeutics Market Analysis and Forecast, by API Peptide Type

  • 11.1. Introduction & Definition
  • 11.2. Key Findings / Developments
  • 11.3. Market Value Forecast, by API Peptide Type ,2017-2031
    • 11.3.1. In-house
    • 11.3.2. CMO
  • 11.4. Market Attractiveness Analysis, by API Peptide Type

12. Global Peptide Therapeutics Market Analysis and Forecast, by Region

  • 12.1. Key Findings
  • 12.2. Market Value Forecast, by Region
    • 12.2.1. North America
    • 12.2.2. Europe
    • 12.2.3. Asia Pacific
    • 12.2.4. Latin America
    • 12.2.5. Middle East & Africa
  • 12.3. Market Attractiveness Analysis, by Region

13. North America Peptide Therapeutics Market Analysis and Forecast

  • 13.1. Introduction
    • 13.1.1. Key Findings
  • 13.2. Market Value Forecast, by Application,2017-2031
    • 13.2.1. Cancer
    • 13.2.2. Metabolic
    • 13.2.3. CVD
    • 13.2.4. Respiratory
    • 13.2.5. GIT
    • 13.2.6. Anti-infective
    • 13.2.7. Dermatology
    • 13.2.8. CNS
    • 13.2.9. Renal
  • 13.3. Market Value Forecast, by End-user,2017-2031
    • 13.3.1. Parenteral
    • 13.3.2. Oral
  • 13.4. Market Value Forecast, by Type, 2017-2031
    • 13.4.1. Innovative
    • 13.4.2. Generic
  • 13.5. Market Value Forecast, by Technology, 2017-2031
    • 13.5.1. Liquid Phase
    • 13.5.2. Solid Phase
    • 13.5.3. Hybrid Phase
  • 13.6. Market Value Forecast, by Type of Molecule, 2017-2031
    • 13.6.1. Vasopressin
    • 13.6.2. Somatostatin
    • 13.6.3. Calcitonin
    • 13.6.4. Natriuretic
  • 13.7. Market Value Forecast, by API Peptide Type, 2017-2031
    • 13.7.1. In-house
    • 13.7.2. CMO
  • 13.8. Market Value Forecast, by Country, 2017-2031
    • 13.8.1. U.S.
    • 13.8.2. Canada
  • 13.9. Market Attractiveness Analysis
    • 13.9.1. By Application
    • 13.9.2. By Route of Administration
    • 13.9.3. By Type
    • 13.9.4. By Technology
    • 13.9.5. By Type of Molecule
    • 13.9.6. By API Peptide Type
    • 13.9.7. By Country

14. Europe Peptide Therapeutics Market Analysis and Forecast

  • 14.1. Introduction
    • 14.1.1. Key Findings
  • 14.2. Market Value Forecast, by Application, 2017-2031
    • 14.2.1. Cancer
    • 14.2.2. Metabolic
    • 14.2.3. CVD
    • 14.2.4. Respiratory
    • 14.2.5. GIT
    • 14.2.6. Anti-infective
    • 14.2.7. Dermatology
    • 14.2.8. CNS
    • 14.2.9. Renal
  • 14.3. Market Value Forecast, by End-user, 2017-2031
    • 14.3.1. Parenteral
    • 14.3.2. Oral
  • 14.4. Market Value Forecast, by Type, 2017-2031
    • 14.4.1. Innovative
    • 14.4.2. Generic
  • 14.5. Market Value Forecast, by Technology, 2017-2031
    • 14.5.1. Liquid Phase
    • 14.5.2. Solid Phase
    • 14.5.3. Hybrid Phase
  • 14.6. Market Value Forecast, by Type of Molecule, 2017-2031
    • 14.6.1. Vasopressin
    • 14.6.2. Somatostatin
    • 14.6.3. Calcitonin
    • 14.6.4. Natriuretic
  • 14.7. Market Value Forecast, by API Peptide Type, 2017-2031
    • 14.7.1. In-house
    • 14.7.2. CMO
  • 14.8. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 14.8.1. Germany
    • 14.8.2. U.K.
    • 14.8.3. France
    • 14.8.4. Spain
    • 14.8.5. Italy
    • 14.8.6. Rest of Europe
  • 14.9. Market Attractiveness Analysis
    • 14.9.1. By Application
    • 14.9.2. By Route of Administration
    • 14.9.3. By Type
    • 14.9.4. By Technology
    • 14.9.5. By Type of Molecule
    • 14.9.6. By API Peptide Type
    • 14.9.7. By Country/Sub-region

15. Asia Pacific Peptide Therapeutics Market Analysis and Forecast

  • 15.1. Introduction
    • 15.1.1. Key Findings
  • 15.2. Market Value Forecast, by Application, 2017-2031
    • 15.2.1. Cancer
    • 15.2.2. Metabolic
    • 15.2.3. CVD
    • 15.2.4. Respiratory
    • 15.2.5. GIT
    • 15.2.6. Anti-infective
    • 15.2.7. Dermatology
    • 15.2.8. CNS
    • 15.2.9. Renal
  • 15.3. Market Value Forecast, by End-user, 2017-2031
    • 15.3.1. Parenteral
    • 15.3.2. Oral
  • 15.4. Market Value Forecast, by Type, 2017-2031
    • 15.4.1. Innovative
    • 15.4.2. Generic
  • 15.5. Market Value Forecast, by Technology, 2017-2031
    • 15.5.1. Liquid Phase
    • 15.5.2. Solid Phase
    • 15.5.3. Hybrid Phase
  • 15.6. Market Value Forecast, by Type of Molecule, 2017-2031
    • 15.6.1. Vasopressin
    • 15.6.2. Somatostatin
    • 15.6.3. Calcitonin
    • 15.6.4. Natriuretic
  • 15.7. Market Value Forecast, by API Peptide Type, 2017-2031
    • 15.7.1. In-house
    • 15.7.2. CMO
  • 15.8. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 15.8.1. China
    • 15.8.2. Japan
    • 15.8.3. India
    • 15.8.4. Australia & New Zealand
    • 15.8.5. Rest of Asia Pacific
  • 15.9. Market Attractiveness Analysis
    • 15.9.1. By Application
    • 15.9.2. By Route of Administration
    • 15.9.3. By Type
    • 15.9.4. By Technology
    • 15.9.5. By Type of Molecule
    • 15.9.6. By API Peptide Type
    • 15.9.7. By Country/Sub-region

16. Latin America Peptide Therapeutics Market Analysis and Forecast

  • 16.1. Introduction
    • 16.1.1. Key Findings
  • 16.2. Market Value Forecast, by Application, 2017-2031
    • 16.2.1. Cancer
    • 16.2.2. Metabolic
    • 16.2.3. CVD
    • 16.2.4. Respiratory
    • 16.2.5. GIT
    • 16.2.6. Anti-infective
    • 16.2.7. Dermatology
    • 16.2.8. CNS
    • 16.2.9. Renal
  • 16.3. Market Value Forecast, by End-user, 2017-2031
    • 16.3.1. Parenteral
    • 16.3.2. Oral
  • 16.4. Market Value Forecast, by Type, 2017-2031
    • 16.4.1. Innovative
    • 16.4.2. Generic
  • 16.5. Market Value Forecast, by Technology,2017-2031
    • 16.5.1. Liquid Phase
    • 16.5.2. Solid Phase
    • 16.5.3. Hybrid Phase
  • 16.6. Market Value Forecast, by Type of Molecule, 2017-2031
    • 16.6.1. Vasopressin
    • 16.6.2. Somatostatin
    • 16.6.3. Calcitonin
    • 16.6.4. Natriuretic
  • 16.7. Market Value Forecast, by API Peptide Type, 2017-2031
    • 16.7.1. In-house
    • 16.7.2. CMO
  • 16.8. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 16.8.1. Brazil
    • 16.8.2. Mexico
    • 16.8.3. Rest of Latin America
  • 16.9. Market Attractiveness Analysis
    • 16.9.1. By Application
    • 16.9.2. By Route of Administration
    • 16.9.3. By Type
    • 16.9.4. By Technology
    • 16.9.5. By Type of Molecule
    • 16.9.6. By API Peptide Type
    • 16.9.7. By Country/Sub-region

17. Middle East & Africa Peptide Therapeutics Market Analysis and Forecast

  • 17.1. Introduction
    • 17.1.1. Key Findings
  • 17.2. Market Value Forecast, by Application, 2017-2031
    • 17.2.1. Cancer
    • 17.2.2. Metabolic
    • 17.2.3. CVD
    • 17.2.4. Respiratory
    • 17.2.5. GIT
    • 17.2.6. Anti-infective
    • 17.2.7. Dermatology
    • 17.2.8. CNS
    • 17.2.9. Renal
  • 17.3. Market Value Forecast, by End-user, 2017-2031
    • 17.3.1. Parenteral
    • 17.3.2. Oral
  • 17.4. Market Value Forecast, by Type, 2017-2031
    • 17.4.1. Innovative
    • 17.4.2. Generic
  • 17.5. Market Value Forecast, by Technology, 2017-2031
    • 17.5.1. Liquid Phase
    • 17.5.2. Solid Phase
    • 17.5.3. Hybrid Phase
  • 17.6. Market Value Forecast, by Type of Molecule, 2017-2031
    • 17.6.1. Vasopressin
    • 17.6.2. Somatostatin
    • 17.6.3. Calcitonin
    • 17.6.4. Natriuretic
  • 17.7. Market Value Forecast, by API Peptide Type, 2017-2031
    • 17.7.1. In-house
    • 17.7.2. CMO
  • 17.8. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 17.8.1. GCC Countries
    • 17.8.2. South Africa
    • 17.8.3. Rest of Middle East & Africa
  • 17.9. Market Attractiveness Analysis
    • 17.9.1. By Application
    • 17.9.2. By Route of Administration
    • 17.9.3. By Type
    • 17.9.4. By Technology
    • 17.9.5. By Type of Molecule
    • 17.9.6. By API Peptide Type
    • 17.9.7. By Country/Sub-region

18. Competition Landscape

  • 18.1. Market Player - Competition Matrix (by tier and size of companies)
  • 18.2. Market Share Analysis, by Company, 2021
  • 18.3. Company Profiles
    • 18.3.1. Amgen, Inc.
      • 18.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 18.3.1.2. Product Portfolio
      • 18.3.1.3. SWOT Analysis
      • 18.3.1.4. Strategic Overview
    • 18.3.2. Bachem Holding AG
      • 18.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 18.3.2.2. Product Portfolio
      • 18.3.2.3. SWOT Analysis
      • 18.3.2.4. Strategic Overview
    • 18.3.3. Eli Lilly and Company
      • 18.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 18.3.3.2. Product Portfolio
      • 18.3.3.3. SWOT Analysis
      • 18.3.3.4. Strategic Overview
    • 18.3.4. F. Hoffmann-La Roche Ltd.
      • 18.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 18.3.4.2. Product Portfolio
      • 18.3.4.3. SWOT Analysis
      • 18.3.4.4. Strategic Overview
    • 18.3.5. GlaxoSmithKline plc
      • 18.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 18.3.5.2. Product Portfolio
      • 18.3.5.3. SWOT Analysis
      • 18.3.5.4. Strategic Overview
    • 18.3.6. Novartis AG
      • 18.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 18.3.6.2. Product Portfolio
      • 18.3.6.3. SWOT Analysis
      • 18.3.6.4. Strategic Overview
    • 18.3.7. Pfizer, Inc.
      • 18.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 18.3.7.2. Product Portfolio
      • 18.3.7.3. SWOT Analysis
      • 18.3.7.4. Strategic Overview
    • 18.3.8. Sanofi
      • 18.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 18.3.8.2. Product Portfolio
      • 18.3.8.3. SWOT Analysis
      • 18.3.8.4. Strategic Overview
    • 18.3.9. Takeda Pharmaceutical Company Limited
      • 18.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 18.3.9.2. Product Portfolio
      • 18.3.9.3. SWOT Analysis
      • 18.3.9.4. Strategic Overview
    • 18.3.10. Teva Pharmaceutical Industries Ltd.
      • 18.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 18.3.10.2. Product Portfolio
      • 18.3.10.3. SWOT Analysis
      • 18.3.10.4. Strategic Overview
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제